Hims Hers Health is trading 10.6% up at $30.28 as healthcare stocks rebound following the August 18 selloff.

  • Healthcare-sector ETF XLV is up 3.23%, supported by stronger earnings expectations, investor rotation and positive cancer-vaccine trial news.
  • No company-specific catalyst for the August 19 move was identified; the August 19 board investigation announcement cited no reason for the rise.
  • Reuters reported a wider Q2 loss tied to branded weight-loss investments and higher costs, a background risk.